KALV

8.30

0.61% 0.05

Handel nachbörslich: 8.30

Kalvista Pharmaceuticals Inc (KALV)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$8.25

Offen:

$8.35

24-Stunden-Volumen:

269.68K

Relative Volume:

0.79

Marktkapitalisierung:

$410.17M

Einnahmen:

Nettoeinkommen (Verlust:

$-108.30M

KGV:

-2.6349

EPS:

-3.15

Netto-Cashflow:

$-97.15M

1W Leistung:

+5.73%

1M Leistung:

-4.05%

6M Leistung:

-44.56%

1J Leistung:

-36.15%

1-Tages-Spanne:

$8.19

$8.42

1-Wochen-Bereich:

$7.30

$8.42

52-Wochen-Spanne:

$7.30

$16.88

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Firmenname

Kalvista Pharmaceuticals Inc

Sektor

Healthcare (1174)

Branche

Biotechnology (684)

Telefon

(857) 999-0075

Adresse

55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA

Mitarbeiter

150

Twitter

@kalvista

Nächster Verdiensttermin

2024-09-05

Neueste SEC-Einreichungen

KALV's Discussions on Twitter

Vergleichen Sie KALV mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KALV Kalvista Pharmaceuticals Inc	8.30	410.17M	0	-108.30M	-97.15M	-3.15
VRTX Vertex Pharmaceuticals Inc	422.00	108.68B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	681.58	74.90B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	640.52	38.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	246.27	31.76B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	111.93	26.83B	3.30B	-501.07M	1.03B	-2.1146

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-01-07	Eingeleitet	TD Cowen	Buy
2024-12-18	Eingeleitet	BofA Securities	Buy
2020-06-15	Eingeleitet	H.C. Wainwright	Buy
2019-07-29	Eingeleitet	SVB Leerink	Outperform
2019-03-20	Eingeleitet	Needham	Buy
2018-10-30	Eingeleitet	Jefferies	Buy
2018-09-21	Eingeleitet	Cantor Fitzgerald	Overweight
2017-08-31	Eingeleitet	BTIG Research	Buy

Alle ansehen

Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten

Jan 19, 2025

KalVista wins new Buy at BofA on potential of lead candidate - MSN

Jan 19, 2025

Jan 16, 2025

Barclays PLC Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jan 16, 2025

Jan 08, 2025

KalVista Pharmaceuticals Awards Strategic Employee Stock Options Worth 111,000 Shares - StockTitan

Jan 08, 2025

TD Cowen Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation - MSN

Jan 08, 2025

TD Cowen backs Kalvista stock as peak sales potential for sebetralstat exceeds $750MM - Investing.com Canada

Jan 08, 2025

Jan 07, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at TD Cowen - MarketBeat

Jan 07, 2025

Jan 02, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Holdings Raised by Geode Capital Management LLC - Defense World

Jan 02, 2025

Jan 01, 2025

Barclays PLC Raises Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jan 01, 2025

Dec 26, 2024

How the (KALV) price action is used to our Advantage - Stock Traders Daily

Dec 26, 2024

Dec 25, 2024

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by State Street Corp - MarketBeat

Dec 25, 2024

State Street Corp Buys 515,179 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Dec 25, 2024

Dec 23, 2024

KalVista Pharmaceuticals Inc (NASDAQ: KALV) Is The Number One Stock Currently Moving. - Stocks Register

Dec 23, 2024

Dec 20, 2024

KALV Stock Touches 52-Week Low at $8.20 Amid Market Challenges - Investing.com Canada

Dec 20, 2024

Dec 18, 2024

KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025 - Seeking Alpha

Dec 18, 2024

BofA Securities sets price target on Kalvista shares with Buy rating - Investing.com Australia

Dec 18, 2024

KalVista stock wins new Buy at BofA (KALV:NASDAQ) - Seeking Alpha

Dec 18, 2024

KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at Bank of America - MarketBeat

Dec 18, 2024

Fmr LLC Increases Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Dec 18, 2024

Dec 17, 2024

KalVista appoints new COO amid operational growth By Investing.com - Investing.com Canada

Dec 17, 2024

Dec 16, 2024

KalVista Pharmaceuticals, Inc. Appoints Jeb Ledell as Chief Operating Officer - Marketscreener.com

Dec 16, 2024

KalVista Appoints Jeb Ledell as Chief Operating Officer - The Bakersfield Californian

Dec 16, 2024

KalVista Pharmaceuticals Taps Former AVEO Oncology Executive as New COO in Strategic Leadership Move - StockTitan

Dec 16, 2024

Dec 13, 2024

KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges - Investing.com Canada

Dec 13, 2024

Dec 12, 2024

KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges By Investing.com - Investing.com South Africa

Dec 12, 2024

Dec 10, 2024

KalVista Pharmaceuticals (NASDAQ:KALV) Given “Overweight” Rating at Cantor Fitzgerald - Defense World

Dec 10, 2024

Dec 09, 2024

KalVista CEO Benjamin Palleiko sells shares worth $74,363 By Investing.com - Investing.com Canada

Dec 09, 2024

KalVista CEO Benjamin Palleiko sells shares worth $74,363 - Investing.com

Dec 09, 2024

What is HC Wainwright's Forecast for KALV FY2029 Earnings? - MarketBeat

Dec 09, 2024

What is HC Wainwright’s Forecast for KALV FY2029 Earnings? - Defense World

Dec 09, 2024

Dec 08, 2024

KALVKalVista Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Dec 08, 2024

Dec 07, 2024

KalVista Pharmaceuticals' (KALV) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Dec 07, 2024

Dec 06, 2024

KalVista shares hold buy rating on HAE drug outlook - Investing.com

Dec 06, 2024

KalVista shares hold buy rating on HAE drug outlook By Investing.com - Investing.com Nigeria

Dec 06, 2024

Dec 05, 2024

KalVista Pharmaceuticals Reports Progress in HAE Treatment - TipRanks

Dec 05, 2024

180,000 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Purchased by Readystate Asset Management LP - MarketBeat

Dec 05, 2024